Analysts’ Viewpoint
The global exosome technologies market is expected to witness significant growth in the next few years due to increase in prevalence of cancer and other chronic diseases. Rise in demand for non-invasive diagnostic and therapeutic techniques is also fueling global exosome technologies market development. Furthermore, rise in investment in R&D activities by several governments and increase in adoption of exosome-based products in drug discovery and development are propelling market expansion.
Rise in demand for personalized medicine offers lucrative opportunities for market players. Manufacturers are engaged in developing exosome-based products to increase market share.
However, high cost of exosome-based products and lack of standardization in isolation and purification techniques are expected to restrain market growth in the next few years. Limited awareness about exosome technologies among healthcare professionals and patients is hampering market dynamics.
Exosomes are small extracellular vesicles that are released by cells and play a crucial role in intercellular communication. These vesicles contain various biomolecules such as proteins, lipids, and nucleic acids, which can be used for diagnostic and therapeutic purposes.
The market includes various products such as isolation kits, characterization kits, and detection kits, which are used for the isolation, purification, and analysis of exosomes. Exosome technologies are used for the diagnosis and treatment of various diseases such as cancer, cardiovascular diseases, and neurological disorders.
Exosomes can be used as biomarkers for disease diagnosis and monitoring, and can also be used as drug-delivery vehicles for targeted therapy. However, one of the major challenges associated with exosome technologies is the heterogeneity of exosomes, which makes their isolation and characterization difficult.
Chronic diseases, such as cancer, cardiovascular diseases, and neurological disorders, are the leading causes of morbidity and mortality across the world. Exosomes, small vesicles secreted by cells, play an important role in cell-to-cell communication and the regulation of several physiological and pathological processes, including the development and progression of chronic diseases.
Exosomes carry several biomolecules, including proteins, nucleic acids, and lipids, which can serve as biomarkers for disease diagnosis and as targets for therapy. The usage of exosomes in the diagnosis and treatment of chronic diseases has been the focus of extensive research in the past few years.
The increase in the prevalence of chronic diseases is driven by several factors, including the aging population, sedentary lifestyles, poor dietary habits, and environmental factors, such as pollution. Globally, around one in three adults suffer from multiple chronic conditions. Six in ten adults in the U.S. have a chronic disease and four in ten adults have two or more.
Exosome-based liquid biopsy has emerged as a promising tool for the non-invasive detection and monitoring of cancer, cardiovascular diseases, and other chronic conditions. Exosomes can also be engineered to deliver therapeutic molecules, such as siRNA, microRNA, and drugs, to target cells, providing a potential new avenue for the treatment of chronic diseases.
Exosomes are gaining popularity within the medical research community, as a type of cell-free therapeutic. Moreover, exosomes play a vital role in several physiological and pathological processes. People are gradually becoming aware of the significant benefits offered by quality diagnostic services when it comes to understanding and treating particular ailments. Manufacturers are increasingly shifting from old to novel development of products to provide effective and rapid diagnosis. This is projected to augment the market in the next few years.
Academic and industrial players are continuously working on enhancing the therapeutic potential of exosomes. Hence, government, public, and private players are taking initiatives to increase funding for research & development. This is fueling market progress. For instance, in December 2020, EVerZom received EUR 1.1 Mn in funding from institutional and private investors to develop its exosome bioproduction platform.
As per the latest exosome technologies market forecast, the loaded cargos exosome type segment is likely to account for a major share during the forecast period, owing to their ability to carry various biomolecules.
Loaded cargos are exosomes that contain specific molecules or cargo that can be used for therapeutic purposes. These exosomes are important for intercellular communication. The increase in demand for targeted drug delivery systems has led to rising in research activities related to loaded cargo exosomes.
Advancements in technology have enabled researchers to isolate and purify loaded cargo exosomes from different cell sources with high specificity and yield. For instance, in June 2021, Norgen Biotek Corp., a Canada-based biotechnology company specializing in sample preparation products for genomics applications, launched its new product ExoPure, which enables efficient isolation of pure extracellular vesicles including loaded cargo exosomes from various biological fluids.
Several pharmaceutical companies are investing significantly in developing therapeutics based on loaded cargo exosomes due to their potential use as exosome technologies for drug delivery. In August 2020, Evox Therapeutics Ltd., a U.K.-based biotechnology company, announced a collaboration with Eli Lilly and Company for the development of RNA interference (RNAi) therapies using Evox's proprietary platform technology that utilizes engineered exosomal drug payloads.
Based on cell sources, the MSCs segment dominated the global market in 2022. MSCs are multipotent stem cells that can differentiate into various cell types such as osteoblasts, chondrocytes, and adipocytes. These cells have been found to secrete large amounts of exosomes containing bioactive molecules such as proteins and nucleic acids which can be used for therapeutic purposes.
Several studies have demonstrated the potential use of MSC-derived exosomes in treating various diseases including cardiovascular disorders and neurological disorders. For instance, in May 2021, Codiak BioSciences, Inc. announced positive preclinical data from its lead program exoASO-STAT6, which utilizes MSC-derived exosomes for targeted delivery of antisense oligonucleotides (ASOs) against STAT6 mRNA for the treatment of asthma.
In March 2021, Thermo Fisher Scientific, Inc., launched its new product Exo-FBS, which enables efficient isolation of pure extracellular vesicles including MSC-derived exosomes from fetal bovine serum.
In terms of application, the diagnostics segment accounted for the largest global exosome technologies market share in 2022. Exosomes have been found to contain specific biomolecules such as proteins and nucleic acids that can be used as diagnostic markers for various diseases including cancer, cardiovascular disorders, and neurological disorders. The ability of exosomes to cross biological barriers, such as the blood-brain barrier, has made them attractive targets for developing non-invasive diagnostic tests.
Several companies are investing significantly in developing exosome technologies-based diagnostics biomarkers. For instance, in January 2021, Bio-Techne Corporation announced a collaboration with Vesigen Therapeutics, Inc., a Canada-based biotechnology company focused on developing engineered extracellular vesicles for therapeutic applications for the development of exosome-based liquid biopsy assays.
In November 2020, NanoView Biosciences, Inc. launched its new product ExoView R100 which enables label-free visualization and quantification of individual exosomes from complex biological samples.
North America is expected to dominate the global market for exosome technologies in the next few years, owing to the presence of major players. As per the latest exosome technologies market report, the U.S. is one of the largest markets for exosome-based products. An increase in the adoption of advanced healthcare technologies coupled with favorable government initiatives has led to a surge in demand for exosome technologies in the region. Furthermore, an increase in funding by private organizations and government bodies toward R&D activities related to cancer diagnosis and treatment using exosomes is fueling the exosome technologies market growth in the region.
Asia Pacific is expected to be the fastest-growing region during the forecast period due to increasing investment by key players in emerging economies such as China and India. These countries have a large patient pool suffering from chronic diseases including cancer which creates exosome technologies market opportunities for companies operating within this space. Additionally, the rise in awareness about personalized medicine among patients along with advancements in biotechnology is contributing to market expansion in this region.
As per the latest exosome technologies market analysis, companies are focusing on strategies such as product launches, divestiture, mergers & acquisitions (M&A), and partnerships to strengthen their position in the industry. AEGLE Therapeutics, Aruna Bio, Inc., Bio-Techne Corporation, Carmine Therapeutics, Inc., Codiak BioSciences, Inc., Creative Biolabs, Danaher Corporation (Beckman Coulter, Inc.), Fujifilm Holdings Corporation, NOVADIP Biosciences S.A., OmniSpirant Limited, and Thermo Fisher Scientific, Inc. are the prominent exosome technologies companies operating worldwide.
Each of these players in the market has been profiled in the exosome technologies industry research report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.
|
Attribute |
Detail |
|
Size in 2022 |
US$ 47.3 Mn |
|
Forecast (Value) in 2031 |
More than US$ 343.5 Mn |
|
Compound Annual Growth Rate (CAGR) |
24.8% |
|
Forecast Period |
2023-2031 |
|
Historical Data Available for |
2017-2021 |
|
Quantitative Units |
US$ Mn for Value |
|
Market Analysis |
It includes key segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, and parent industry overview. |
|
Competition Landscape |
|
|
Format |
Electronic (PDF) + Excel |
|
Market Segmentation |
|
|
Regions Covered |
|
|
Countries Covered |
|
|
Companies Profiled |
|
|
Customization Scope |
Available upon request |
|
Pricing |
Available upon request |
The global industry was valued at US$ 47.3 Mn in 2022
It is projected to reach more than US$ 343.5 Mn by 2031
It is anticipated to advance at a CAGR of 24.8% from 2023 to 2031
Surge in prevalence of chronic diseases, increase in awareness about exosome technologies, and rise in government initiatives to increase funding for research & development are driving the market
The loaded cargos exosome type segment accounted for major share in 2022
North America is expected to be a highly lucrative region from 2023 to 2031
AEGLE Therapeutics, Aruna Bio, Inc., Bio-Techne Corporation (Exosome Diagnostics, Inc.), Carmine Therapeutics, Inc., Codiak BioSciences, Inc., Creative Biolabs, Danaher Corporation (Beckman Coulter, Inc.), Fujifilm Holdings Corporation, NOVADIP Biosciences S.A., OmniSpirant Limited, and Thermo Fisher Scientific, Inc.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Exosome Technologies Market
4. Market Overview
4.1. Introduction
4.1.1. Exosome Type Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Exosome Technologies Market Analysis and Forecasts, 2017 - 2031
4.4.1. Market Revenue Projections (US$ Mn)
4.4.2. Market Volume/Unit Shipments Projections
5. Key Insights
5.1. Pipeline Analysis
5.2. Technological Advancements
5.3. COVID-19 Pandemic Impact on Industry (value chain and short/mid/long term impact)
6. Global Exosome Technologies Market Analysis and Forecasts, by Exosome Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast By Exosome Type, 2017 - 2031
6.3.1. Loaded Cargos
6.3.1.1. Peptide
6.3.1.2. siRNA
6.3.1.3. mRNA
6.3.1.4. miRNA
6.3.1.5. Protein
6.3.1.6. Chemical
6.3.1.7. Others
6.3.2. Non-cargo
6.4. Market Attractiveness By Exosome Type
7. Global Exosome Technologies Market Analysis and Forecasts, by Cell Source
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast By Cell Source, 2017 - 2031
7.3.1. HEK293 Cells
7.3.2. MSCs
7.3.3. Platelets
7.3.4. Erythrocytes
7.3.5. Natural Killer Cells
7.3.6. Others
7.4. Market Attractiveness By Cell Source
8. Global Exosome Technologies Market Analysis and Forecasts, by Application
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast By Application, 2017 - 2031
8.3.1. Therapeutics
8.3.1.1. Oncology
8.3.1.2. Neurodegenerative Diseases
8.3.1.3. Cardiovascular Diseases
8.3.1.4. Infectious Diseases
8.3.1.5. Cosmetics
8.3.2. Diagnostics
8.4. Market Attractiveness By Application
9. Global Exosome Technologies Market Analysis and Forecasts, by End-user
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Market Value Forecast By End-user, 2017 - 2031
9.3.1. Health Care Providers
9.3.2. Pharmaceutical & Biotechnology Companies
9.3.3. Others
9.4. Market Attractiveness By End-user
10. Global Exosome Technologies Market Analysis and Forecasts, by Region
10.1. Key Findings
10.2. Market Value Forecast By Region
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness By Country/Region
11. North America Exosome Technologies Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast By Exosome Type, 2017 - 2031
11.2.1. Loaded Cargos
11.2.1.1. Peptide
11.2.1.2. siRNA
11.2.1.3. mRNA
11.2.1.4. miRNA
11.2.1.5. Protein
11.2.1.6. Chemical
11.2.1.7. Others
11.2.2. Non-cargo
11.3. Market Value Forecast By Cell Source, 2017 - 2031
11.3.1. HEK293 Cells
11.3.2. MSCs
11.3.3. Platelets
11.3.4. Erythrocytes
11.3.5. Natural Killer Cells
11.3.6. Others
11.4. Market Value Forecast By Application, 2017 - 2031
11.4.1. Therapeutics
11.4.1.1. Oncology
11.4.1.2. Neurodegenerative Diseases
11.4.1.3. Cardiovascular Diseases
11.4.1.4. Infectious Diseases
11.4.1.5. Cosmetics
11.4.2. Diagnostics
11.5. Market Value Forecast By End-user, 2017 - 2031
11.5.1. Health Care Providers
11.5.2. Pharmaceutical & Biotechnology Companies
11.5.3. Others
11.6. Market Value Forecast By Country, 2017 - 2031
11.6.1. U.S.
11.6.2. Canada
11.7. Market Attractiveness Analysis
11.7.1. By Exosome Type
11.7.2. By Cell Source
11.7.3. By Application
11.7.4. By End-user
11.7.5. By Country
12. Europe Exosome Technologies Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast By Exosome Type, 2017 - 2031
12.2.1. Loaded Cargos
12.2.1.1. Peptide
12.2.1.2. siRNA
12.2.1.3. mRNA
12.2.1.4. miRNA
12.2.1.5. Protein
12.2.1.6. Chemical
12.2.1.7. Others
12.2.2. Non-cargo
12.3. Market Value Forecast By Cell Source, 2017 - 2031
12.3.1. HEK293 Cells
12.3.2. MSCs
12.3.3. Platelets
12.3.4. Erythrocytes
12.3.5. Natural Killer Cells
12.3.6. Others
12.4. Market Value Forecast By Application, 2017 - 2031
12.4.1. Therapeutics
12.4.1.1. Oncology
12.4.1.2. Neurodegenerative Diseases
12.4.1.3. Cardiovascular Diseases
12.4.1.4. Infectious Diseases
12.4.1.5. Cosmetics
12.4.2. Diagnostics
12.5. Market Value Forecast By End-user, 2017 - 2031
12.5.1. Health Care Providers
12.5.2. Pharmaceutical & Biotechnology Companies
12.5.3. Others
12.6. Market Value Forecast By Country, 2017 - 2031
12.6.1. Germany
12.6.2. U.K.
12.6.3. France
12.6.4. Spain
12.6.5. Italy
12.6.6. Rest of Europe
12.7. Market Attractiveness Analysis
12.7.1. By Exosome Type
12.7.2. By Cell Source
12.7.3. By Application
12.7.4. By End-user
12.7.5. By Country
13. Asia Pacific Exosome Technologies Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast By Exosome Type, 2017 - 2031
13.2.1. Loaded Cargos
13.2.1.1. Peptide
13.2.1.2. siRNA
13.2.1.3. mRNA
13.2.1.4. miRNA
13.2.1.5. Protein
13.2.1.6. Chemical
13.2.1.7. Others
13.2.2. Non-cargo
13.3. Market Value Forecast By Cell Source, 2017 - 2031
13.3.1. HEK293 Cells
13.3.2. MSCs
13.3.3. Platelets
13.3.4. Erythrocytes
13.3.5. Natural Killer Cells
13.3.6. Others
13.4. Market Value Forecast By Application, 2017 - 2031
13.4.1. Therapeutics
13.4.1.1. Oncology
13.4.1.2. Neurodegenerative Diseases
13.4.1.3. Cardiovascular Diseases
13.4.1.4. Infectious Diseases
13.4.1.5. Cosmetics
13.4.2. Diagnostics
13.5. Market Value Forecast By End-user, 2017 - 2031
13.5.1. Health Care Providers
13.5.2. Pharmaceutical & Biotechnology Companies
13.5.3. Others
13.6. Market Value Forecast By Country, 2017 - 2031
13.6.1. China
13.6.2. Japan
13.6.3. India
13.6.4. Australia & New Zealand
13.6.5. Rest of Asia Pacific
13.7. Market Attractiveness Analysis
13.7.1. By Exosome Type
13.7.2. By Cell Source
13.7.3. By Application
13.7.4. By End-user
13.7.5. By Country
14. Latin America Exosome Technologies Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast By Exosome Type, 2017 - 2031
14.2.1. Loaded Cargos
14.2.1.1. Peptide
14.2.1.2. siRNA
14.2.1.3. mRNA
14.2.1.4. miRNA
14.2.1.5. Protein
14.2.1.6. Chemical
14.2.1.7. Others
14.2.2. Non-cargo
14.3. Market Value Forecast By Cell Source, 2017 - 2031
14.3.1. HEK293 Cells
14.3.2. MSCs
14.3.3. Platelets
14.3.4. Erythrocytes
14.3.5. Natural Killer Cells
14.3.6. Others
14.4. Market Value Forecast By Application, 2017 - 2031
14.4.1. Therapeutics
14.4.1.1. Oncology
14.4.1.2. Neurodegenerative Diseases
14.4.1.3. Cardiovascular Diseases
14.4.1.4. Infectious Diseases
14.4.1.5. Cosmetics
14.4.2. Diagnostics
14.5. Market Value Forecast By End-user, 2017 - 2031
14.5.1. Health Care Providers
14.5.2. Pharmaceutical & Biotechnology Companies
14.5.3. Others
14.6. Market Value Forecast By Country, 2017 - 2031
14.6.1. Brazil
14.6.2. Mexico
14.6.3. Rest of Latin America
14.7. Market Attractiveness Analysis
14.7.1. By Exosome Type
14.7.2. By Cell Source
14.7.3. By Application
14.7.4. By End-user
14.7.5. By Country
15. Middle East & Africa Exosome Technologies Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast By Exosome Type, 2017 - 2031
15.2.1. Loaded Cargos
15.2.1.1. Peptide
15.2.1.2. siRNA
15.2.1.3. mRNA
15.2.1.4. miRNA
15.2.1.5. Protein
15.2.1.6. Chemical
15.2.1.7. Others
15.2.2. Non-cargo
15.3. Market Value Forecast By Cell Source, 2017 - 2031
15.3.1. HEK293 Cells
15.3.2. MSCs
15.3.3. Platelets
15.3.4. Erythrocytes
15.3.5. Natural Killer Cells
15.3.6. Others
15.4. Market Value Forecast By Application, 2017 - 2031
15.4.1. Therapeutics
15.4.1.1. Oncology
15.4.1.2. Neurodegenerative Diseases
15.4.1.3. Cardiovascular Diseases
15.4.1.4. Infectious Diseases
15.4.1.5. Cosmetics
15.4.2. Diagnostics
15.5. Market Value Forecast By End-user, 2017 - 2031
15.5.1. Health Care Providers
15.5.2. Pharmaceutical & Biotechnology Companies
15.5.3. Others
15.6. Market Value Forecast By Country, 2017 - 2031
15.6.1. GCC Countries
15.6.2. South Africa
15.6.3. Rest of Middle East & Africa
15.7. Market Attractiveness Analysis
15.7.1. By Exosome Type
15.7.2. By Cell Source
15.7.3. By Application
15.7.4. By End-user
15.7.5. By Country
16. Competition Landscape
16.1. Market Player – Competition Matrix (By Tier and Size of companies)
16.2. Market Share Analysis By Company (2021)
16.3. Company Profiles
16.3.1. AEGLE Therapeutics
16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.1.2. Test Type Portfolio
16.3.1.3. Financial Overview
16.3.1.4. SWOT Analysis
16.3.1.5. Strategic Overview
16.3.2. Aruna Bio, Inc.
16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.2.2. Test Type Portfolio
16.3.2.3. Financial Overview
16.3.2.4. SWOT Analysis
16.3.2.5. Strategic Overview
16.3.3. Bio-Techne Corporation (Exosome Diagnostics, Inc.)
16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.3.2. Test Type Portfolio
16.3.3.3. Financial Overview
16.3.3.4. SWOT Analysis
16.3.3.5. Strategic Overview
16.3.4. Carmine Therapeutics, Inc.
16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.4.2. Test Type Portfolio
16.3.4.3. Financial Overview
16.3.4.4. SWOT Analysis
16.3.4.5. Strategic Overview
16.3.5. Codiak BioSciences, Inc.
16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.5.2. Test Type Portfolio
16.3.5.3. Financial Overview
16.3.5.4. SWOT Analysis
16.3.5.5. Strategic Overview
16.3.6. Creative Biolabs
16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.6.2. Test Type Portfolio
16.3.6.3. Financial Overview
16.3.6.4. SWOT Analysis
16.3.6.5. Strategic Overview
16.3.7. Danaher Corporation (Beckman Coulter, Inc.)
16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.7.2. Test Type Portfolio
16.3.7.3. Financial Overview
16.3.7.4. SWOT Analysis
16.3.7.5. Strategic Overview
16.3.8. Fujifilm Holdings Corporation
16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.8.2. Test Type Portfolio
16.3.8.3. Financial Overview
16.3.8.4. SWOT Analysis
16.3.8.5. Strategic Overview
16.3.9. NOVADIP Biosciences S.A.
16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.9.2. Test Type Portfolio
16.3.9.3. Financial Overview
16.3.9.4. SWOT Analysis
16.3.9.5. Strategic Overview
16.3.10. OmniSpirant Limited
16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.10.2. Test Type Portfolio
16.3.10.3. Financial Overview
16.3.10.4. SWOT Analysis
16.3.10.5. Strategic Overview
16.3.11. Thermo Fisher Scientific, Inc.
16.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.11.2. Test Type Portfolio
16.3.11.3. Financial Overview
16.3.11.4. SWOT Analysis
16.3.11.5. Strategic Overview
List of Tables
Table 01: Global Exosome Technologies Market Value (US$ Mn) Forecast, by Exosome Type, 2017-2031
Table 02: Global Exosome Technologies Market Value (US$ Mn) Forecast, by Loaded Cargos, 2017-2031
Table 03: Global Exosome Technologies Market Value (US$ Mn) Forecast, by Cell Source, 2017-2031
Table 04: Global Exosome Technologies Market Value (US$ Mn) Forecast, by Application, 2017-2031
Table 05: Global Exosome Technologies Market Value (US$ Mn) Forecast, by Therapeutics, 2017-2031
Table 06: Global Exosome Technologies Market Value (US$ Mn) Forecast, by End-user, 2017-2031
Table 07: Global Exosome Technologies Market Value (US$ Mn) Forecast, by Region, 2017-2031
Table 08: North America Exosome Technologies Market Value (US$ Mn) Forecast, by Country, 2017-2031
Table 09: North America Exosome Technologies Market Value (US$ Mn) Forecast, by Exosome Type, 2017-2031
Table 10: North America Exosome Technologies Market Value (US$ Mn) Forecast, by Loaded Cargos, 2017-2031
Table 11: North America Exosome Technologies Market Value (US$ Mn) Forecast, by Cell Source, 2017-2031
Table 12: North America Exosome Technologies Market Value (US$ Mn) Forecast, by Application, 2017-2031
Table 13: North America Exosome Technologies Market Value (US$ Mn) Forecast, by Therapeutics, 2017-2031
Table 14: North America Exosome Technologies Market Value (US$ Mn) Forecast, by End-user, 2017-2031
Table 15: Europe Exosome Technologies Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 16: Europe Exosome Technologies Market Value (US$ Mn) Forecast, by Exosome Type, 2017-2031
Table 17: Europe Exosome Technologies Market Value (US$ Mn) Forecast, by Loaded Cargos, 2017-2031
Table 18: Europe Exosome Technologies Market Value (US$ Mn) Forecast, by Cell Source, 2017-2031
Table 19: Europe Exosome Technologies Market Value (US$ Mn) Forecast, by Application, 2017-2031
Table 20: Europe Exosome Technologies Market Value (US$ Mn) Forecast, by Therapeutics, 2017-2031
Table 21: Europe Exosome Technologies Market Value (US$ Mn) Forecast, by End-user, 2017-2031
Table 22: Asia Pacific Exosome Technologies Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 23: Asia Pacific Exosome Technologies Market Value (US$ Mn) Forecast, by Exosome Type, 2017-2031
Table 24: Asia Pacific Exosome Technologies Market Value (US$ Mn) Forecast, by Loaded Cargos, 2017-2031
Table 25: Asia Pacific Exosome Technologies Market Value (US$ Mn) Forecast, by Cell Source, 2017-2031
Table 26: Asia Pacific Exosome Technologies Market Value (US$ Mn) Forecast, by Application, 2017-2031
Table 27: Asia Pacific Exosome Technologies Market Value (US$ Mn) Forecast, by Therapeutics, 2017-2031
Table 28: Asia Pacific Exosome Technologies Market Value (US$ Mn) Forecast, by End-user, 2017-2031
Table 29: Latin America Exosome Technologies Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 30: Latin America Exosome Technologies Market Value (US$ Mn) Forecast, by Exosome Type, 2017-2031
Table 31: Latin America Exosome Technologies Market Value (US$ Mn) Forecast, by Loaded Cargos, 2017-2031
Table 32: Latin America Exosome Technologies Market Value (US$ Mn) Forecast, by Cell Source, 2017-2031
Table 33: Latin America Exosome Technologies Market Value (US$ Mn) Forecast, by Application, 2017-2031
Table 34: Latin America Exosome Technologies Market Value (US$ Mn) Forecast, by Therapeutics, 2017-2031
Table 35: Latin America Exosome Technologies Market Value (US$ Mn) Forecast, by End-user, 2017-2031
Table 36: Middle East & Africa Exosome Technologies Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 37: Middle East & Africa Exosome Technologies Market Value (US$ Mn) Forecast, by Exosome Type, 2017-2031
Table 38: Middle East & Africa Exosome Technologies Market Value (US$ Mn) Forecast, by Loaded Cargos, 2017-2031
Table 39: Middle East & Africa Exosome Technologies Market Value (US$ Mn) Forecast, by Cell Source, 2017-2031
Table 40: Middle East & Africa Exosome Technologies Market Value (US$ Mn) Forecast, by Application, 2017-2031
Table 41: Middle East & Africa Exosome Technologies Market Value (US$ Mn) Forecast, by Therapeutics, 2017-2031
Table 42: Middle East & Africa Exosome Technologies Market Value (US$ Mn) Forecast, by End-user, 2017-2031
List of Figures
Figure 01: Global Exosome Technologies Market Value (US$ Mn) Forecast, 2017-2031
Figure 02: Global Exosome Technologies Market Value Share Analysis, by Exosome Type, 2022 and 2031
Figure 03: Global Exosome Technologies Market Attractiveness Analysis, by Exosome Type, 2023-2031
Figure 04: Global Exosome Technologies Market (US$ Mn), by Loaded Cargos, 2017-2031
Figure 05: Global Exosome Technologies Market (US$ Mn), by Non-cargo, 2017-2031
Figure 06: Global Exosome Technologies Market Value Share Analysis, by Cell Source, 2022 and 2031
Figure 07: Global Exosome Technologies Market Attractiveness Analysis, by Cell Source, 2023-2031
Figure 08: Global Exosome Technologies Market (US$ Mn), by HEK293 Cells, 2017-2031
Figure 09 Global Exosome Technologies Market (US$ Mn), by MSCs, 2017-2031
Figure 10: Global Exosome Technologies Market (US$ Mn), by Platelets, 2017-2031
Figure 11: Global Exosome Technologies Market (US$ Mn), by Erythrocytes, 2017-2031
Figure 12: Global Exosome Technologies Market (US$ Mn), by Natural Killer Cells, 2017-2031
Figure 13: Global Exosome Technologies Market (US$ Mn), by Others, 2017-2031
Figure 14: Global Exosome Technologies Market Value Share Analysis, by Application, 2022 and 2031
Figure 15: Global Exosome Technologies Market Attractiveness Analysis, by Application, 2023-2031
Figure 16: Global Exosome Technologies Market (US$ Mn), by Therapeutics, 2017-2031
Figure 17: Global Exosome Technologies Market (US$ Mn), by Diagnostics, 2017-2031
Figure 18: Global Exosome Technologies Market Value Share Analysis, by End-user, 2022 and 2031
Figure 19: Global Exosome Technologies Market Attractiveness Analysis, by End-user, 2023-2031
Figure 20: Global Exosome Technologies Market (US$ Mn), by Health Care Providers, 2017-2031
Figure 21: Global Exosome Technologies Market (US$ Mn), by Pharmaceutical & Biotechnology Companies, 2017-2031
Figure 22: Global Exosome Technologies Market (US$ Mn), by Others, 2017-2031
Figure 23: Global Exosome Technologies Market Value Share Analysis, by Region, 2022 and 2031
Figure 24: Global Exosome Technologies Market Attractiveness Analysis, by Region, 2023-2031
Figure 25: North America Exosome Technologies Market Value (US$ Mn) Forecast, 2017-2031
Figure 26: North America Exosome Technologies Market Value Share Analysis, by Country, 2022 and 2031
Figure 27: North America Exosome Technologies Market Attractiveness Analysis, by Country, 2023-2031
Figure 28: North America Exosome Technologies Market Value Share Analysis, by Exosome Type, 2022 and 2031
Figure 29: North America Exosome Technologies Market Attractiveness Analysis, by Exosome Type, 2023-2031
Figure 30: North America Exosome Technologies Market Value Share Analysis, by Cell Source, 2022 and 2031
Figure 31: North America Exosome Technologies Market Attractiveness Analysis, by Cell Source, 2023-2031
Figure 32: North America Exosome Technologies Market Value Share Analysis, by Application, 2022 and 2031
Figure 33: North America Exosome Technologies Market Attractiveness Analysis, by Application, 2023-2031
Figure 34: North America Exosome Technologies Market Value Share Analysis, by End-user, 2022 and 2031
Figure 35: North America Exosome Technologies Market Attractiveness Analysis, by End-user, 2023-2031
Figure 36: Europe Exosome Technologies Market Value (US$ Mn) Forecast, 2017-2031
Figure 37: Europe Exosome Technologies Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 38: Europe Exosome Technologies Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 39: Europe Exosome Technologies Market Value Share Analysis, by Exosome Type, 2022 and 2031
Figure 40: Europe Exosome Technologies Market Attractiveness Analysis, by Exosome Type, 2023-2031
Figure 41: Europe Exosome Technologies Market Value Share Analysis, by Cell Source, 2022 and 2031
Figure 42: Europe Exosome Technologies Market Attractiveness Analysis, by Cell Source, 2023-2031
Figure 43: Europe Exosome Technologies Market Value Share Analysis, by Application, 2022 and 2031
Figure 44: Europe Exosome Technologies Market Attractiveness Analysis, by Application, 2023-2031
Figure 45: Europe Exosome Technologies Market Value Share Analysis, by End-user, 2022 and 2031
Figure 46: Europe Exosome Technologies Market Attractiveness Analysis, by End-user, 2023-2031
Figure 47: Asia Pacific Exosome Technologies Market Value (US$ Mn) Forecast, 2017-2031
Figure 48: Asia Pacific Exosome Technologies Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 49: Asia Pacific Exosome Technologies Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 50: Asia Pacific Exosome Technologies Market Value Share Analysis, by Exosome Type, 2022 and 2031
Figure 51: Asia Pacific Exosome Technologies Market Attractiveness Analysis, by Exosome Type, 2023-2031
Figure 52: Asia Pacific Exosome Technologies Market Value Share Analysis, by Cell Source, 2022 and 2031
Figure 53: Asia Pacific Exosome Technologies Market Attractiveness Analysis, by Cell Source, 2023-2031
Figure 54: Asia Pacific Exosome Technologies Market Value Share Analysis, by Application, 2022 and 2031
Figure 55: Asia Pacific Exosome Technologies Market Attractiveness Analysis, by Application, 2023-2031
Figure 56: Asia Pacific Exosome Technologies Market Value Share Analysis, by End-user, 2022 and 2031
Figure 57: Asia Pacific Exosome Technologies Market Attractiveness Analysis, by End-user, 2023-2031
Figure 58: Latin America Exosome Technologies Market Value (US$ Mn) Forecast, 2017-2031
Figure 59: Latin America Exosome Technologies Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 60: Latin America Exosome Technologies Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 61: Latin America Exosome Technologies Market Value Share Analysis, by Exosome Type, 2022 and 2031
Figure 62: Latin America Exosome Technologies Market Attractiveness Analysis, by Exosome Type, 2023-2031
Figure 63: Latin America Exosome Technologies Market Value Share Analysis, by Cell Source, 2022 and 2031
Figure 64: Latin America Exosome Technologies Market Attractiveness Analysis, by Cell Source, 2023-2031
Figure 65: Latin America Exosome Technologies Market Value Share Analysis, by Application, 2022 and 2031
Figure 66: Latin America Exosome Technologies Market Attractiveness Analysis, by Application, 2023-2031
Figure 67: Latin America Exosome Technologies Market Value Share Analysis, by End-user, 2022 and 2031
Figure 68: Latin America Exosome Technologies Market Attractiveness Analysis, by End-user, 2023-2031
Figure 69: Middle East & Africa Exosome Technologies Market Value (US$ Mn) Forecast, 2017-2031
Figure 70: Middle East & Africa Exosome Technologies Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 71: Middle East & Africa Exosome Technologies Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 72: Middle East & Africa Exosome Technologies Market Value Share Analysis, by Exosome Type, 2022 and 2031
Figure 73: Middle East & Africa Exosome Technologies Market Attractiveness Analysis, by Exosome Type, 2023-2031
Figure 74: Middle East & Africa Exosome Technologies Market Value Share Analysis, by Cell Source, 2022 and 2031
Figure 75: Middle East & Africa Exosome Technologies Market Attractiveness Analysis, by Cell Source, 2023-2031
Figure 76: Middle East & Africa Exosome Technologies Market Value Share Analysis, by Application, 2022 and 2031
Figure 77: Middle East & Africa Exosome Technologies Market Attractiveness Analysis, by Application, 2023-2031
Figure 78: Middle East & Africa Exosome Technologies Market Value Share Analysis, by End-user, 2022 and 2031
Figure 79: Middle East & Africa Exosome Technologies Market Attractiveness Analysis, by End-user, 2023-2031
Figure 80: Global Exosome Technologies Market Share Analysis, by Company, 2022
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Exosome Technologies Market
